Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general financial performance.
Material Changes
Following a revaluation of the cash element of the notional investment held within the GSK 401K plan, there was an increase in the notional allocation of American Depositary Shares (ADSs) on January 31, 2014. The transaction price was $51.54 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items regarding the company's operations or financial future. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Type: Increase in notional ADS allocation within the GSK 401K plan due to revaluation.
- Transaction Date: January 31, 2014 (notified February 3, 2014).
- Price: $51.54 per ADS.
- Directors/PDMRs Affected: Dr. M M Slaoui (17 ADSs) and Dr. K Slaoui (4 ADSs).
- Financial Data: No company-wide financial metrics are disclosed in this specific filing.